Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial
Clinical Microbiology and Infection · 2023
DOI: 10.1016/j.cmi.2023.08.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Marianna Riekkinen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Infectious Disease…. Hauptthemen laut MEDLINE: Hepatitis A, Pneumococcal Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVES: We explored the influence of coadministration on safety and immunogenicity of the most common travellers' vaccine hepatitis A (HepA) and the pneumococcal conjugate vaccine (PCV) increasingly used both at home and before travel. METHODS: Volunteers aged ≥18 years (n = 305) were randomly assigned 1:1:1 into three groups receiving: 13-valent PCV (PCV13) + HepA, PCV13, or HepA. Anti-pneumococcal IgG concentrations, opsonophagocytic activity (OPA) titres, and total hepatitis A antibody (anti-HAV) concentrations were measured before and 28 ± 3 days after vaccination. Adverse events (AEs) were recorded over 4 weeks. RESULTS: After vaccination, the anti-HAV geometric mean concentration was significantly lower in the PCV13+HepA than the HepA group: 34.47 mIU/mL (95% CI: 26.42-44.97 mIU/mL) versus 72.94 mIU/mL (95% CI: 55.01-96.72 mIU/mL), p < 0.001. Anti-HAV ≥10 mIU/mL considered protective was reached by 71 of 85 (83.5%) in the PCV13+HepA group versus 76 of 79 (96.2%) in the HepA group, p 0.008. The increases in anti-pneumococcal IgG and OPA levels were comparable in the PCV13+HepA and PCV13 groups, apart from a bigger rise in the PCV13+HepA group for serotype 3 (one-way ANOVA: serotype 3 IgG p 0.010, OPA p 0.002). AEs proved more frequent among those receiving PCV13 than HepA, but simultaneous administration did not increase the rates: ≥one AE was reported by 45 of 56 (80.4%) PCV13, 43 of 54 (79.6%) PCV13+HepA, and 25 of 53 (47.2%) HepA recipients providing structured AE data. DISCUSSION: Coadministration of HepA and PCV13 did not cause safety concerns, nor did it impact the patients' response to PCV13, apart from serotype 3. However, coadministered PCV13 significantly impaired antibody responses to HepA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Helsinki, Finlan…
- Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Human Microbiome Research Unit, University of Helsinki, Helsinki, Finland.
- National Reference Centre of Hepatitis Viruses, Infectious Diseases in Humans, Sciensano Laboratory, Brussels, Belgium.
- Infectious Disease Control and Vaccination Unit, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.
- Department of Medical Biochemistry and Microbiology, Zoonosis Science Center, Uppsala University, Uppsala, Sweden; Centre for Clinical Research, Sörmland County Council, Eskilstuna, Sweden.
Zitieren
APA
Riekkinen, M., Pakkanen, S. H., Hutse, V., Roukaerts, I., Ollgren, J., Käyhty, H., Herzog, C., Rombo, L., & Kantele, A. (2023). Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.08.006
Vancouver
Riekkinen M, Pakkanen SH, Hutse V, Roukaerts I, Ollgren J, Käyhty H, et al. Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.08.006
BibTeX
@article{Riekkinen2023,
author = {Riekkinen, Marianna and Pakkanen, Sari H and Hutse, Veronik and Roukaerts, Inge and Ollgren, Jukka and Käyhty, Helena and Herzog, Christian and Rombo, Lars and Kantele, Anu},
title = {Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial},
journal = {Clinical Microbiology and Infection},
year = {2023},
doi = {10.1016/j.cmi.2023.08.006}
}
EUVIMED